← Leaderboards
Hushan Yang
Thomas Jefferson University
$4,413,023
Attributed
$6,531,252
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $916K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,531,252 · 5
By mechanism
R01$5,857,539 · 2
R21$370,838 · 1
R03$302,875 · 2
Top collaborators
- William K. Kelly5 shared
- Grace Lu-Yao5 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Mark A Feitelson$9,601,309
- Flemming Forsberg$18,638,328
- John Eisenbrey$7,634,263
- Walter John Curran$19,392,586
- Edouard John Trabulsi$2,221,350
Others in their field
Top investigators on “Follow-Up”
- Jeffrey P Krischer · University Of South Florida$398,381,597
- James Dennis Neaton · Northwestern University$283,212,546
- Gregory H Reaman · National Childhood Cancer Foundation$201,951,987
- Judith S Hochman · New York University School Of Medicine$125,409,158
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$119,981,780
- David R. Weir · University Of Michigan At Ann Arbor$119,885,186
Research focus
Follow-UpTissuesMalignant NeoplasmsValidationMalignant - DescriptorTumorGenesResearch DesignBaseNeoplasm MetastasisCharacteristicsBiopsyIndividual PatientBloodGene PanelGenetic SignatureHigh RiskLiquid BiopsyExhibitsGenomic ProfilesExome SequencingCellsData AnalysesIndividualized Medicine
Grant awards (17)
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$653,812
R01 · FY2025 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$607,916
R01 · FY2024 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$626,097
R01 · FY2023 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$596,405
R01 · FY2022 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$319,558
R01 · FY2022 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$693,113
R01 · FY2021 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$67,103
R01 · FY2021 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$596,374
R01 · FY2020 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$611,093
R01 · FY2019 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$587,218
R01 · FY2018 · CA · contact PI
A population-based approach to single CTC analysis in metastatic breast cancer outcome$498,850
R01 · FY2017 · CA · contact PI
Tumor microRNA signatures as prognostic biomarkers of colorectal cancer$72,850
R03 · FY2013 · CA · contact PI
Serum microRNA signature as prospective HCC biomarker in HBV patients$168,563
R21 · FY2012 · CA · contact PI
Tumor microRNA signatures as prognostic biomarkers of colorectal cancer$77,500
R03 · FY2012 · CA · contact PI
Serum microRNA signature as prospective HCC biomarker in HBV patients$202,275
R21 · FY2011 · CA · contact PI
Inflammation Variants and Risk of Hepatocellular Carcinoma in HBV Patients$75,175
R03 · FY2011 · CA · contact PI
Inflammation Variants and Risk of Hepatocellular Carcinoma in HBV Patients$77,350
R03 · FY2010 · CA · contact PI